23rd American Pharma & Biotech Project, Program and Portfolio Conference

16–18 Oct 2024 | Boston, Massachusetts, United States

Anusha Sivaramakrishnan

Executive Director, Head - Enterprise Project Management and Governance

Arvinas

New York, United States

17 profile visitsSpeakerSpeaker

My organisation

Arvinas

Arvinas

Manufacturer

New York, United States

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com.
Read more

About me

My organisation

Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com.

Social media

Speaker sessions (3)

Wednesday, 16 October 2024

11:00 - 11:30

PANEL DISCUSSION: Organizational processes behind decision making

Format:In-personLocation:Beacon Hill Ballroom
  • Deciding On The Right Mix Of Therapeutic Areas

Thursday, 17 October 2024

08:30 - 09:00

15:30 - 16:00

PANEL DISCUSSION: Incorporating diversity and inclusion across organization

Format:In-personLocation:Beacon Hill Ballroom
  • Break-Out Sessions